Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

398.27
Delayed Data
As of Jul 26
 +3.37 / +0.85%
Today’s Change
329.09
Today|||52-Week Range
605.93
-26.64%
Year-to-Date
Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week
Jul 22 / TheStreet.com - Paid Partner Content
Pfizer Publishes Final Data from Atopic Dermatitis Studies
Jul 14 / Zacks.com - Paid Partner Content
Why I Bought Shares of Regeneron Pharmaceuticals Inc. Last Week
Jul 20 / MotleyFool.com - Paid Partner Content
Here's Why Regeneron Pharmaceuticals, Inc. Dropped Another 12% in June
Jul 13 / MotleyFool.com - Paid Partner Content
3 Biotech Stocks to Buy and Hold
Jul 19 / MotleyFool.com - Paid Partner Content
Wall Street set for best week since late 2014 as stocks rebound
Jul 01 / FT.com - Paid Partner Content

Today’s Trading

Previous close394.90
Today’s open393.00
Day’s range390.01 - 398.65
Volume593,704
Average volume (3 months)918,960
Market cap$41.5B
Dividend yield--
Data as of 3:59pm ET, 07/26/2016

Growth & Valuation

Earnings growth (last year)+79.80%
Earnings growth (this year)-9.59%
Earnings growth (next 5 years)+20.00%
Revenue growth (last year)+45.55%
P/E ratio63.2
Price/Sales15.24
Price/Book11.31

Competitors

 Today’s
change
Today’s
% change
ALXNAlexion Pharmaceutic...-0.81-0.64%
SHPGShire+1.31+0.68%
ZTSZoetis Inc-0.07-0.14%
MYLMylan NV-0.80-1.69%
Data as of 4:03pm ET, 07/26/2016

Financials

Next reporting dateAugust 2, 2016
EPS forecast (this quarter)$2.65
Annual revenue (last year)$4.1B
Annual profit (last year)$636.1M
Net profit margin15.50%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Leonard S. Schleifer
Chief Financial Officer &
Senior VP-Finance
Robert E. Landry
Corporate headquarters
Tarrytown, New York

Forecasts

Partner Offers

Search for Jobs